医学
心包炎
羟基氯喹
硫唑嘌呤
心肌炎
冠状动脉疾病
疾病
系统性红斑狼疮
人口
环磷酰胺
心脏病学
重症监护医学
皮肤病科
内科学
化疗
传染病(医学专业)
环境卫生
2019年冠状病毒病(COVID-19)
作者
Nicole K. Zagelbaum,Carlos Linares-Koloffon,Alba Posligua,Liliya Gandrabur,Woo Young Kim,Kirk Sperber,Amy Wasserman,Julia Ash
出处
期刊:Cardiology in Review
[Ovid Technologies (Wolters Kluwer)]
日期:2020-09-29
卷期号:30 (1): 38-43
被引量:23
标识
DOI:10.1097/crd.0000000000000358
摘要
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
科研通智能强力驱动
Strongly Powered by AbleSci AI